Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

17.02
-0.0200-0.12%
Post-market: 17.020.00000.00%19:30 EDT
Volume:683.74K
Turnover:11.64M
Market Cap:882.12M
PE:16.29
High:17.05
Open:17.03
Low:17.02
Close:17.04
52wk High:21.03
52wk Low:13.08
Shares:51.83M
Float Shares:25.86M
Volume Ratio:1.86
T/O Rate:2.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.05
EPS(LYR):2.06
ROE:20.91%
ROA:1.33%
PB:3.04
PE(LYR):8.26

Loading ...

Theravance Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Ireland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth

Reuters
·
May 07

Theravance Biopharma Q1 net loss narrows to $4.93 million; revenue rises 15% to $17.7 million

Reuters
·
May 07

Theravance Biopharma Inc: Restructuring Is Expected to Impact About 50% of the Overall Workforce

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Full Run-Rate Cost Savings of About$70 Mln Expected to Fully Materialize in Q3

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Expects to Incur About $5 to $7 Million in One-Time Cash Severance Costs Related to Restructuring Actions

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Restructuring Will Involve Winding Down R&D Function and Significantly Reducing G&a Function

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc - Strategic Review Committee Actively Evaluating Opportunities to Maximize Shareholder Value

THOMSON REUTERS
·
May 07

Theravance Biopharma Q1 Net Income USD -4.933 Million

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Implementing an Organizational Restructuring to Streamline Costs and Align Its Resources

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Restructuring Is Expected to Reduce Operating Expenses by About 60%

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Restructuring Actions Expected to Be Implemented Over Next 2 Quarters

THOMSON REUTERS
·
May 07

Theravance Biopharma announces annual general meeting

Reuters
·
Apr 29

Theravance Biopharma Is Maintained at Neutral by B. Riley Securities

Dow Jones
·
Apr 08

B. Riley Raises Price Target on Theravance Biopharma to $17 From $14, Keeps Neutral Rating

MT Newswires Live
·
Apr 07

Theravance Secures Long-Term YUPELRI Patent Litigation Settlement

TIPRANKS
·
Mar 31

Theravance Biopharma Inc -Co's Units and Mylan Enter Settlement Agreement With Mankind on Yupelri Litigation - SEC Filing

THOMSON REUTERS
·
Mar 31

Theravance Biopharma: Theravance & Mylan Granted Mankind License to Market Generic Yupelri in U.S. on or After April 23, 2039

THOMSON REUTERS
·
Mar 31

Theravance Biopharma Inc - Settlement Subject to Review by U.S. Department of Justice and Federal Trade Commission - SEC Filing

THOMSON REUTERS
·
Mar 31

Theravance, Viatris settle Yupelri patent suit, allow Mankind generic launch in 2039

Reuters
·
Mar 31